Squamous Cell Carcinoma - Pipeline Review, H1 2012

Global Markets Direct, April 2012, Pages: 355

Squamous Cell Carcinoma – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Squamous Cell Carcinoma - Pipeline Review, H1 2012', provides an overview of the Squamous Cell Carcinoma therapeutic pipeline. This report provides information on the therapeutic development for Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma. 'Squamous Cell Carcinoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Squamous Cell Carcinoma.
- A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Squamous Cell Carcinoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Squamous Cell Carcinoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Squamous Cell Carcinoma pipeline depth and focus of Squamous Cell Carcinoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Squamous Cell Carcinoma Therapeutic Products under Development, Key Players in Squamous Cell Carcinoma Therapeutics, Squamous Cell Carcinoma Pipeline Overview, Squamous Cell Carcinoma Pipeline, Squamous Cell Carcinoma Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Squamous Cell Carcinoma Overview
Therapeutics Development
An Overview of Pipeline Products for Squamous Cell Carcinoma
Squamous Cell Carcinoma Therapeutics under Development by Companies
Squamous Cell Carcinoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Squamous Cell Carcinoma Therapeutics – Products under Development by Companies
Squamous Cell Carcinoma Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Squamous Cell Carcinoma Therapeutics Development
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Shionogi & Co., Ltd.
Amgen Inc.
Sanofi-Aventis
Eli Lilly and Company
Viralytics Ltd.
GlaxoSmithKline plc
Symphogen A/S
Piramal Healthcare Limited
Celltrion, Inc.
Millennium Pharmaceuticals, Inc.
ImClone Systems Incorporated
Eisai Co., Ltd.
Pfizer Inc.
Takara Holdings Inc.
Yakult Honsha Co., Ltd.
Merck KGaA
InNexus Biotechnology Inc.
Idera Pharmaceuticals, Inc.
NexMed, Inc.
Clinuvel Pharmaceuticals Limited
Oncolytics Biotech Inc.
Oncothyreon Inc
Jennerex Biotherapeutics, Inc.
Innogene Kalbiotech Pte Ltd.
Omeros Corporation
IRX Therapeutics, Inc.
Eurofarma
Biotech Pharmaceuticals Co., Ltd.
Squamous Cell Carcinoma – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
IMO-2055 - Drug Profile
MLN8237 - Drug Profile
Sym004 - Drug Profile
BSI-201 - Drug Profile
LY2523355 - Drug Profile
Scenesse - Drug Profile
Vectibix - Drug Profile
IRX-2 - Drug Profile
Tykerb - Drug Profile
Cisplatin + Gemcitabine + Docetaxel - Drug Profile
Oxaliplatin + Pemetrexed Disodium - Drug Profile
Paclitaxel + Cisplatin + Radiation Therapy - Drug Profile
Cetuximab - Drug Profile
Temsirolimus + Paclitaxel + Carboplatin - Drug Profile
Cisplatin + Cetuximab + Temsirolimus - Drug Profile
Pemetrexed + Erlotinib + Radiation Therapy - Drug Profile
Sorafenib - Drug Profile
Tarceva - Drug Profile
Cetuximab + Paclitaxel + Cisplatin - Drug Profile
Cetuximab + Docetaxel + Cisplatin - Drug Profile
Torisel + Tarceva - Drug Profile
Paclitaxel + Carboplatin + 5-Fluorouracil + Bevacizumab + Erlotinib + Radiation Therapy - Drug Profile
Isotretinoin + Interferon Alpha 2a - Drug Profile
Cisplatin + Radiation Therapy - Drug Profile
Sutent + Gemcitabine - Drug Profile
Carboplatin + Taxol + RAD001 - Drug Profile
Platinol + Taxotere + Tarceva - Drug Profile
Carboplatin + Radiotherapy - Drug Profile
Cisplatin + Radiation Therapy1 - Drug Profile
Nimotuzumab + Docetaxel + Cisplatin + Fluorouracil - Drug Profile
Dasatinib - Drug Profile
Fenretinide - Drug Profile
Bevacizumab - Drug Profile
Erbitux + Cisplatin + 5-Fluorouracil - Drug Profile
Vectibix + Cisplatin + Radiation Therapy - Drug Profile
Vectibix + Cisplatin + 5-FU - Drug Profile
Tirapazamine + Cisplatin - Drug Profile
Reolysin + Paclitaxel + Carboplatin - Drug Profile
Afatinib - Drug Profile
E7389 - Drug Profile
Xeloda + Eloxatin + Radiation Therapy - Drug Profile
Nimotuzumab + Cisplatin + Radiation Therapy - Drug Profile
Cetuximab + Cisplatin + 5-Fluorouracil - Drug Profile
EMD 1201081 + Cetuximab - Drug Profile
Cetuximab + Carboplatin + 5-Fluorouracil - Drug Profile
Lapatinib + Cisplatin + Radiation Therapy - Drug Profile
Pemetrexed + Cetuximab + Carboplatin - Drug Profile
Pemetrexed + Cetuximab + Cisplatin - Drug Profile
Cisplatin + Carboplatin + Radiotherapy - Drug Profile
Cixutumumab + Erbitux - Drug Profile
Iressa - Drug Profile
MPI 5010 + Carboplatin + Paclitaxel - Drug Profile
Nimotuzumab + Cisplatin + 5-FU + Radiation Therapy - Drug Profile
Cilengitide + Cetuximab + Cisplatin + 5-Fluorouracil - Drug Profile
RAD001 - Drug Profile
Cetuximab + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Cetuximab + Radiation - Drug Profile
Necitumumab + Gemcitabine + Cisplatin - Drug Profile
Cetuximab + IMC-A12 - Drug Profile
Erbitux - Drug Profile
Cetuximab + Carboplatin + Paclitaxel + Radiation Therapy - Drug Profile
Panitumumab + Radiation Therapy - Drug Profile
GW572016 + Radiation Therapy - Drug Profile
Irinotecan + Cisplatin - Drug Profile
mFOLFIRI + Nimotuzumab - Drug Profile
Cetuximab + Carboplatin + Radiotherapy - Drug Profile
Carboplatin + Amrubicin - Drug Profile
Paclitaxel + Cisplatin + Cetuximab + Radiation Therapy - Drug Profile
Tarceva + Cisplatin + Paclitaxel - Drug Profile
Cisplatin + Radiation Therapy - Drug Profile
Topotecan + Cisplatin - Drug Profile
Tarceva + Cisplatin + Radiation Therapy - Drug Profile
Carboplatin + Gemcitabine + Paclitaxel - Drug Profile
PX-866 + Docetaxel - Drug Profile
Taxotere + Oxaliplatin - Drug Profile
Carboplatin + TS-1 - Drug Profile
Cisplatin + Gemcitabine - Drug Profile
Cytosine Arabinoside + Cisplatin - Drug Profile
cetuximab - Drug Profile
Carboplatin + Cisplatin + Docetaxel + Fluorouracil + Lapatinib + Radiation Therapy - Drug Profile
Velcade + Taxotere - Drug Profile
Cetuximab + Cisplatin + Radiation Therapy - Drug Profile
Docetaxel + Cisplatin + Cetuximab - Drug Profile
Erbitux + Radiation Therapy - Drug Profile
Cialis - Drug Profile
F-18 Fluorothymidine + Radiation Therapy - Drug Profile
Nimotuzumab + Radiotherapy - Drug Profile
Fluorouracil + Cisplatin + Radiation Therapy - Drug Profile
Taxol - Drug Profile
Carboplatin + Radiation Therapy - Drug Profile
Nedaplatin + Docetaxel - Drug Profile
Cisplatin + Docetaxel - Drug Profile
Irinotecan + Nedaplatin - Drug Profile
Nimotuzumab + Docetaxel + Cisplatin + Fluorouracil1 - Drug Profile
Cisplatin + Docetaxel + Panitumumab - Drug Profile
Suberoylanilide Hydroxamic Acid - Drug Profile
Temsirolimus - Drug Profile
Tykerb + Chemoradiation - Drug Profile
Cisplatin + Carboplatin - Drug Profile
Nimotuzumab + Cisplatin + Radiation Therapy - Drug Profile
Taxotere + Tarceva + Platinol - Drug Profile
Cetuximab - Drug Profile
Cetuximab - Drug Profile
Cisplatin + Ifosfamide + Taxol - Drug Profile
Iressa + Radiation Therapy - Drug Profile
Panitumumab + Radiation Theraphy - Drug Profile
Docetaxel + Cisplatinum + 5-Fluorouracil + Cetuximab + Radiation Therapy - Drug Profile
Cetuximab + Dasatinib + Cisplatin + Radiation Therapy - Drug Profile
Gemcitabine + Docetaxel - Drug Profile
Cisplatin + Vinorelbine - Drug Profile
Cyclophosphamide - Drug Profile
Gemcitabine + Nedaplatin - Drug Profile
EGFR Antisense DNA - Drug Profile
Epirubicin + Cisplatin + Xeloda + Radiation Therapy - Drug Profile
Cetuximab + Cisplatin + Radiation Therapy - Drug Profile
Sorafenib + Carboplatin + Paclitaxel - Drug Profile
Sorafenib + Cetuximab - Drug Profile
Cetuximab + Radiation Therapy - Drug Profile
AG-013736 - Drug Profile
Docetaxel + Cisplatin + 5-Fluorouracil - Drug Profile
Cetuximab + Cisplatin + Taxotere + 5-FU + Radiation Therapy - Drug Profile
LY2523355 + Pegfilgrastim - Drug Profile
Bevacizumab + Cisplatin + Etoposide + Radiation Therapy - Drug Profile
Cisplatin + Paclitaxel + Radiation Therapy - Drug Profile
Docetaxel + Cisplatin + 5-Fluorouracil - Drug Profile
Lapatinib Ditosylate + Capecitabine - Drug Profile
Nimotuzumab - Drug Profile
Carboplatin + S-1 - Drug Profile
Temsirolimus + Cisplatin + Cetuximab - Drug Profile
Erbitux + Radiation Therapy - Drug Profile
Erbitux + Cisplatin + Radiation Therapy - Drug Profile
Cetuximab + Radiotherapy - Drug Profile
Bleomycin + Mitomycin C + Cisplatin - Drug Profile
Erlotinib + Radiation Therapy - Drug Profile
S-488410 - Drug Profile
PX-866 + Erbitux - Drug Profile
Cetuximab + Paclitaxel + Cisplatin + Radiation Therapy - Drug Profile
Nab-Paclitaxel + Cisplatin - Drug Profile
Docetaxel + Cisplatin + Fluorouracil + Carboplatin + Cetuximab + Radiation Therapy - Drug Profile
P276 + Radiation Therapy - Drug Profile
Docetaxel + Radiotherapy - Drug Profile
AT-101 + Docetaxel - Drug Profile
Vectibix + Mitomicin C + 5-Fluorouracil + Radiation Therapy - Drug Profile
Nimotuzumab + Cisplatin + Radiation Therapy - Drug Profile
Docetaxel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile
Docetaxel + Cisplatin + 5-Fluorouracil + Cetuximab + Radiation Therapy - Drug Profile
Carboplatin + Cetuximab + RAD001 - Drug Profile
E7050 + Cetuximab - Drug Profile
Axitinib + Cisplatin + Gemcitabine - Drug Profile
Paclitaxel + Cisplatin - Drug Profile
Docetaxel + Cisplatin + Fluorouracil - Drug Profile
Cetuximab + Nab-Paclitaxel + Carboplatin - Drug Profile
ZD6474 - Drug Profile
Satraplatin + Radiation Therapy - Drug Profile
Cetuximab + OSI-906 - Drug Profile
TPF Induction Chemotherapy + Radiotherapy - Drug Profile
Squamous Cell Carcinoma Therapeutics – Drug Profile Updates
Squamous Cell Carcinoma Therapeutics – Discontinued Products
Squamous Cell Carcinoma Therapeutics - Dormant Products
Squamous Cell Carcinoma – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Squamous Cell Carcinoma, H1 2012
Products under Development for Squamous Cell Carcinoma – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
Boehringer Ingelheim GmbH, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Shionogi & Co., Ltd., H1 2012
Amgen Inc., H1 2012
Sanofi-Aventis, H1 2012
Eli Lilly and Company, H1 2012
Viralytics Ltd., H1 2012
GlaxoSmithKline plc, H1 2012
Symphogen A/S, H1 2012
Piramal Healthcare Limited, H1 2012
Celltrion, Inc., H1 2012
Millennium Pharmaceuticals, Inc., H1 2012
ImClone Systems Incorporated, H1 2012
Eisai Co., Ltd., H1 2012
Pfizer Inc., H1 2012
Takara Holdings Inc., H1 2012
Yakult Honsha Co., Ltd., H1 2012
Merck KGaA, H1 2012
InNexus Biotechnology Inc., H1 2012
Idera Pharmaceuticals, Inc., H1 2012
NexMed, Inc., H1 2012
Clinuvel Pharmaceuticals Limited, H1 2012
Oncolytics Biotech Inc., H1 2012
Oncothyreon Inc, H1 2012
Jennerex Biotherapeutics, Inc., H1 2012
Innogene Kalbiotech Pte Ltd., H1 2012
Omeros Corporation, H1 2012
IRX Therapeutics, Inc., H1 2012
Eurofarma, H1 2012
Biotech Pharmaceuticals Co., Ltd., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Squamous Cell Carcinoma Therapeutics – Drug Profile Updates
Squamous Cell Carcinoma Therapeutics – Discontinued Products
Squamous Cell Carcinoma Therapeutics – Discontinued Products (Contd..1)
Squamous Cell Carcinoma Therapeutics – Dormant Products
Squamous Cell Carcinoma Therapeutics – Dormant Products (Contd..1)
Squamous Cell Carcinoma Therapeutics – Dormant Products (Contd..2)
Squamous Cell Carcinoma Therapeutics – Dormant Products (Contd..3)
Squamous Cell Carcinoma Therapeutics – Dormant Products (Contd..4)
Squamous Cell Carcinoma Therapeutics – Dormant Products (Contd..5)
Squamous Cell Carcinoma Therapeutics – Dormant Products (Contd..6)
Squamous Cell Carcinoma Therapeutics – Dormant Products (Contd..7)

List of Figures
Number of Products under Development for Squamous Cell Carcinoma, H1 2012
Products under Development for Squamous Cell Carcinoma – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2013
• Cervical Cancer - Pipeline Review, H2 2012
• Bladder Cancer - Pipeline Review, H2 2012
• Brain Cancer - Pipeline Review, H2 2012
• Head And Neck Cancer - Pipeline Review, H2 2012
• Adenocarcinoma - Pipeline Review, H2 2012
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2012
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
• Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2012
• Head And Neck Cancer - Pipeline Review, Q4 2010